XXVI International Comprehensive Course on Epidemiology and Control of Tuberculosis 3 to 11 April 2017 in Lima, Peru

Agenda: 3 April 8.00-8.30 Registration 8.30-9.00 Opening remarks Introduction of participants and facilitators 9.00-9.30 **Pre-Course Evaluation Test** 9.30-10.00 Learning objectives of the course 10.00-11.00 Origin and History of the TB. Can the TB be erradicated in the next decades? 11.00-11.15 **Break** 11.15-12.15 Biological characteristics and condition of M. tuberculosis Growth 12.15-13.15 Basic concepts in TB. Bacillary populations of M. tuberculosis. Relapses, Failures, Defaulters, bad adherence 13.15-14.15 Lunch 14.15-15.00 Epidemiology of tuberculosis and drug resistance in the country Global epidemiology of TB and MDR-TB 15.00-16.00 Analysis of factors contributing to MDR- and XDR-TB Transmissibility, virulence and fitness of resistant strains of *M. tuberculosis* and its possible influence for the future 16.00-16.15 **Break** 16.15-18.00 Working Groups (4-5 groups with 4-5 participants). Practical exercises addressing the topics presented in the day. Discussion of national TB and MDR/XDR-TB Cases 4 April 8.00-8.45 Review of the Highlights Day 1 8.45-10.00 Diagnosis of the Infection TB. Tuberculin skin test and IGRAs 10.00-11.00 Clinical and Radiography manifestations of TB 11.00-11.15 **Break** 11.15-12-30 Conventional laboratory procedures: Smear, culture and Identification of species 12.30-13.15 Other procedures supporting the TB diagnosis: histologic findings, adenosine desaminase (ADA), and others

13.15-14.15

Lunch

14.15-16.00	Drug resistant TB can be curable and aviodable
16.15-18.00	Working Groups (4-5 groups with 4-5 participants). Practical exercises
10.13-16.00	
	addressing the topics reviewed in the day.
	Discussion of national X/MDR-TB Cases
5 April	
8.00-8.45	Review of the Highlights Day 2
8.45-11.00	Basic concepts in drug resistance
	Natural resistance. Primary or initial resistance (new drug resistance)
	Secondary or acquired resistance (previously treated drug resistance)
	Transient resistance. Poly-resistance, MDR and XDR
	Possibilities of drug resistant afer failures, relapses, defaulters and poor
	adherence
11.00-11.15	Break
11.15-13.15	Diagnosis of drug resistant tuberculosis
	Risk factors for drug resistance. Classification of MDR-TB
	The importance of the history of previous drug intake by patient and drug
	utilization in the country.
	Support of the Drug susceptibility testing for management of drug resistant TB.
	Reliability.
	Techniques for rapid diagnosis of drug resistant TB (LPA, Xpert, etc)
13.15-14.15	Lunch
14.15-16.00	Infection control - minimal requirements given limited resources
16.00-16.15	Break
16.15-18.00	Working Groups (4-5 groups with 4-5 participants). Practical exercises
	addressing the topics reviewed in the day.
	Discussion of national X/MDR-TB Cases
6 April	
8.00-8.45	Review of the Highlights Day 3
8.45-10.00	Initial Treatment of TB. Principles
	Intermittent regimens.
	Special situations in the treatment of the TB
10.00-11.00	Treatment of the TB According the Pattern of Resistance (1)
	Treatment of Susceptible TB
	Treatment of Mono-Poly Resistant TB

11.00-11.15 Break

11.15-13-15	Treatment of the TB According the Pattern of Resistance (2)
	Treatment of MDR/XDR-TB
	Duration of the intensive and continuation phase of treatment.
	Role of the surgery in the management of drug resistant TB.
	Standardized and individualized treatment regimens.
13.15-14.15	Lunch
14.15-16.00	Tuberculosis, MDR-/XDR-TB, and HIV. Update and management
16.00-16.15	Break
16.15-18.00	Working Groups (4-5 groups with 4-5 participants). Practical exercises
	addressing the topics reviewed in the day.
	Discussion of national X/MDR-TB Cases
7 April	
8.00-9.00	Review of the Highlights of the Course
9.00-11.00	Reasoning the best treatment options for a NTP
	What is the best Category I Regimen to recommend in a NTP?
	Category II regimen - origin and current rationale
	Which is the most appropriate approach for:
	- Relapses and Defaulters to Category I regimen
	- Failures to Category I regimen
	- Failures to Category II regimen
	- MDR-TB Patients in the different scenarios
11.00-11.15	Break
11.15-12.45	Adverse Reactions to First and Second Line Drugs
	Practical approaches and appropriate management.
12.45-13.15	Avoiding the stigma with the TB patients. Ethical issues in the management of
	TB patients
13.15-14.15	Lunch

8-11 April

14.15-18.00 Practical Exercises

Field Visits (health's centres, laboratories, central unit of the NTP), Information system, technical assistance methodology and other operational issues